Replies to post #120587 on Amarantus Bioscience Holdings Inc (AMBS)

[GoClippers]

During the fourth quarter of 2015 and first quarter of 2016, Amarantus intends to engage the FDA regarding ESS in the filing of applications for rare pediatric disease designation, fast-track designation, orphan drug designation (ODD) and breakthrough designation pathways, as well as other pathways designed to accelerate time to approval.

The priority review voucher if we apply and receive will be a HUGE milestone and will put AMBS in a different league altogether. Does anyone know if AMBS is applying for one?